Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

140.38 +0.75 (+0.54%)
Streaming Delayed Price Updated: 3:10 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials ↗
Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results. 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Insights into Belite Bio's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
From Lin BioScience, Inc.
Via GlobeNewswire
News headline image
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
From Belite Bio, Inc
Via GlobeNewswire
News headline image
BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 ↗
BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the JonesHealthcare Seaside Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.